Skip to main content
SpringerLink
Log in

Selective Estrogen Receptor Modulators

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stockard CR, Papanicolaou GN. The existence of a typical oestrous cycle in the guinea pig with a study of its histological and physiological changes. tiAmer J Anat 1917;22:225-228.

    Google Scholar 

  2. Riggs BL. Overview of osteoporosis. West J Med 1991;154:63-77.

    Google Scholar 

  3. Grandy D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med 1992;117:1016-1037.

    Google Scholar 

  4. Lindsay R, Aitken JM, Anderson JB. Long-term prevention of post-menopausal osteoporosis by estrogen. Lancet 1976;1:1038-1041.

    Google Scholar 

  5. Hulley S, Grady D, Bush T, Furberf C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and estrogen/progestin replacement study (HERS) research group. J Amer Med Assoc 1998;280:605-613.

    Google Scholar 

  6. Grese TA, Sluka JP, Bryant HU, Cullinan GC, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl Acad Sci. 1997;94:14105-14110.

    Google Scholar 

  7. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Green GL, Gustafsson JA. Molecular basis of agonism and antagonism in the estrogen receptor. Nature 1997;389:753-768.

    Google Scholar 

  8. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard A, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-937.

    Google Scholar 

  9. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU. J Clin Invest 1994;93:659-669.

    Google Scholar 

  10. Jerome CP, Lees CJ, Registar TC, Stancill M. Effects of raloxifene on bone density, histomorphometric, and biomechanical measures in ovariectomized cynomolgus monkeys. Bone (in press).

  11. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium is postemenopausal women. New Engl J Med 1997;337:1641-1647.

    Google Scholar 

  12. Adrian MD, Cole HW, Shetler PK, Rowley ER, Magee DE, Pell T, Zeng G, Sato M, Bryant HU. Comparative pharmacology of a series of selective estrogen receptor modulators. J Bone Mineral Res. 1996;11(Suppl. 1):S447.

    Google Scholar 

  13. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel project. J Natl Cancer Inst 1994;86:527-537.

    Google Scholar 

  14. Silfen SL, Ciaccia AV, Bryant HU. Selective estrogen receptor modulators: Tissue specificity and differential uterine effects. Climacteric 1999;2:268-283.

    Google Scholar 

  15. Carthew P, Edwards RE, Nolan BM, Tucker MJ, Smith LL. Compartmentalized uterotrophic effects of tamoxifen, toremifene and estradiol in the ovariectomized Wistar rat. Toxicol Sci 1999;48:197-205.

    Google Scholar 

  16. Cole HW, Adrian MD, Shetler PK, Sato M, Rowley ER, Glasebrook AL, Short LL, Grese TA, Palkowitz AD, Thrasher KJ, Bryant HU. Comparative pharmacology of high potency selective estrogen receptor modulators: LY353381 • HCL and CP-336,156. J Bone Mineral Res 1997;12(Suppl. 1):S349.

    Google Scholar 

  17. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P, Tompson DD. Effects of CP336,156, a new, non-steroidal estrogen agonist/antagonist on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998;139:2068-2076.

    Google Scholar 

  18. Komm BS, Miller CP, Lyttle CR, Way-140424, a third generation tissue selective estrogen with a potentially improved therapeutic profile. J Bone Mineral Res 2000;15(Suppl. 1):S161.

    Google Scholar 

  19. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU. LY353381 ? HC1: A novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 1998;287:1-7.

    Google Scholar 

  20. Martel C, Picard S, Belanger RV, Labrie C, Labrie F. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Molec Biol 2000;74:45-56.

    Google Scholar 

  21. Ronkin S, Clarke L, Boudes P, Constantine G. TSE-424, a novel tissue selective estrogen estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. J Bone Mineral Res 2001;16(Suppl. 1):S413.

    Google Scholar 

  22. Maenpaa JU, Ala-Fossi SL. Toremefine in post-menopausal breast cancer. Efficacy, safety and cost. Drugs Aging 1997;11:261-270.

    Google Scholar 

  23. Goldstein SR, Neven P, Zhou L, Taylor YL, Ciaccia AV, Plouffe L. The effect of raloxifene on the frequency of pelvic floor relaxation. Obstetr Gynecol 2000;98:91-96.

    Google Scholar 

  24. Fuchs-Young R, Magee D, Cole HW, Short L, Glasebrook AL, Rippy MK, Termine JD, Bryant HU. Raloxifene is a tissues specific anti-estrogen that blocks tamoxifen or estrogen stimulated uterotropic effets. Endocrinology 1995;136(Suppl.):57.

    Google Scholar 

  25. Swisher DK, Tague RM, Seyler DE. Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats. Drug Dev Res 1995;36:43-45.

    Google Scholar 

  26. Fanning PM, Kuehl TJ, Lee R, Pearson L, Wincek TJ, Pliego JF, Spiekerman AM, Bryant HU, Rippy MK. Video mapping to assess efficacy of an antiestrogen (Raloxifene) on spontaneous endometriosis in the Rhesus Monkey. American Society Reproductive Medicine 1997.

  27. Porter KB, Tsibris JC, Porter GW, Fuchs-Young, R, Nicosia SV, O'Brien WF, Spellacy WN. Effects of raloxifene in a guinea pig model for leiomyomas. Amer J Obstet Gynecol 1998;170:1283-1287.

    Google Scholar 

  28. Wakeling AE, Valcaccia B. Antiestrogenic and antitumor activities of a series of non-steroidal antiestrogens. J Endocrinol 1987;99:455-464.

    Google Scholar 

  29. Barrett-Connor E. Hormone replacement and cancer. Br Med Bull 1992;48:345-355.

    Google Scholar 

  30. Speroff L. Post-Menopausal hormone therapy and breast cancer. Obstetr Gynecol 1996;87(Suppl. 2):44S-54S.

    Google Scholar 

  31. Cauley JA, Norton L, Lippman ME. Continued breast cancer reduction in post-menopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Research and Treatment 2001;65:125-134.

    Google Scholar 

  32. Short LL, Glasebrook AL, Adrian MD, Cole H, Shetler P, Rowley ER, Magee DE, Pell T, Zeng G, Sato M, Bryant HU. Distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferation. J Bone Mineral Res 1996;11(Suppl. 1):S482.

    Google Scholar 

  33. Sato M, Glasebrook AL, Bryant HU. Raloxifene: A selective estrogen receptor modulator. J Bone Miner Res 1995;12(Suppl. 2):S9-S20.

    Google Scholar 

  34. Labrie F, Veilleuz R, Fournier A. Glucocorticoids stimulates growth of mouse mammary caracinoma Shionogi cells in culture. Mol Cell Endocrinol 1988;58:207-211.

    Google Scholar 

  35. Thompson EW, Reich R, Shima TB, Albina A, Graf J, Martin GR, Dickson RB, Lippman ME. Differential regulation of growth and invasiveness of MCF-7 breast cancer by antiestrogens. Cancer Res 1988;48:6764-6768.

    Google Scholar 

  36. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene LY156758, on growth of caracinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983;32:2869-2875.

    Google Scholar 

  37. Gottardis MM, Jordan VC. Antitumor actions on keoxifene and tamoxifen in the N-nitrosomethylurea induced rat mammary carcinoma model. Cancer Res 1987;4020-4024.

  38. Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, Pearce HL, Williams C, Peeer C, Wang Y, Sporn MB. Arzoxifene, a new SERM for chemoprevention of experimental breast cancer. Cancer Res 2001;61:8412-8415.

    Google Scholar 

  39. Hamm JT. Phase I and II studiees toremifene. Oncology 1997;11 (Suppl. 4):19-22.

    Google Scholar 

  40. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine and estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905-912.

    Google Scholar 

  41. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994:135:2001-2005.

    Google Scholar 

  42. Jilka RL, Hangoi G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 1992;257:88-91.

    Google Scholar 

  43. Glasebrook AL, Short LL, Cole HW, Sato M, Bryant HU. Regulation of serum IL-6 by raloxifene in an ovariectomized rat model. Bone 1995;19(Suppl. 1):99S.

    Google Scholar 

  44. Miyaura C, Onoe Y, Inada M, Maki K, Ikuta K, Ito M, Suda T. Increased B-lymphopoeisis by interleukin-7 induces bone loss in mice with intact ovarian function: Similarity to estrogen deficiency. Proc Natl Acad Sci 1997;94:9360-9365.

    Google Scholar 

  45. Yang NN, Hardikar S, Sato M, Galvin, RJS, Glasebrook AL, Bryant HU, Termine JD. Estrogen and raloxifene stimulate transforming growth Factor-?3 expression in rat bone: A potential mechanism for estrogen or raloxifene-mediated bone maintenance. Endocrinology 1996;137:2075-2084.

    Google Scholar 

  46. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCl, tamoxifen estrogen and alendronate. Bone 1996;18:621-627.

    Google Scholar 

  47. Evans G, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994;134:2283-2288.

    Google Scholar 

  48. Sato M, Bryant HU, Iversen P, Helterbrand J, Smietana F, Bemis K, Higgs R, Turner C, Owan I, Takano Y, Burr DB. Advantages of raloxifene over alendronate or estrogen on non-reproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J Pharmacol Exp Ther 1996;279:298-305.

    Google Scholar 

  49. Hotchkiss CE, Stavisky R, Nowak J, Brommage R, Lees CJ, Kaplan J. Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys. Bone 2001;29:7-15.

    Google Scholar 

  50. Ettinger, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta J, Stakestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: Results form a 3-year randomized clinical trial. J Amer Med Assoc 1999;282:637-645.

    Google Scholar 

  51. Kauffman RF, Bensch WR, Roudebush RE, Cole HW, Bean JS, Philipps D, Monroe A, Cullinan GJ, Glasebrook AL, Bryant HU. Hypocholesterolemic activity of a raloxifene (LY139481): Pharmacological characterization as a selective estrogen receptor modulator (SERM). J Pharmacol Exp Ther 1997;280:146-153.

    Google Scholar 

  52. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed, rabbits. Circulation 1997;96:1964-1969.

    Google Scholar 

  53. Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL, Walsh BW. Effects of raloxifene and hormone replacement theory on markers of serum atherogenicity in healthy post-menopausal women. Maturitas 2000;39:71-77.

    Google Scholar 

  54. Mosca L, Harper K, Sarkar S, O'Gorman J, Anderson PW, Cox DA, Barrett-Conner E. Effect of raloxifene on serum triglycerides in post-menopausal women: Influence of predisposing factors for hypertriglyceridemia 2001;23:1552-1565.

    Google Scholar 

  55. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene. Atherosclerosis 1996;126:65-75.

    Google Scholar 

  56. Wiernicki T, Glasebrook AL, Phillips DL, Singh JP. Estrogen and a novel tissue selective estrogen receptor modulator raloxifene directly modulate vascular smooth muscle cell functions: Implications in the cardioprotective mechanism of estrogen. Circulation 1996:94(8 Suppl. I):1278.

    Google Scholar 

  57. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999;100:1095-1101.

    Google Scholar 

  58. Simoncini T, DeCaterina R, Genazzani AR. Selective estrogen receptor modulators: Different actions on vascular cell adhesion molecule (VCAM-1) expression in human endothelial cells. J Aclin Endocrinol Metab 1999;84:815-818.

    Google Scholar 

  59. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of post-menopausal monkeys. J Clin Endocrinol Metab 1998;83:721-726.

    Google Scholar 

  60. Gaynor JS, Monnet E, Selzman C, Parker D, Kaufman L, Byant HU, Mallinckrodt C, Wrigley R, Whitehill T, Turner AS. The effect of raloxifene on coronary arteries in aged ovariectomized ewes. J Vet Pharmacol Ther 2000;23:175-179.

    Google Scholar 

  61. Baetta R. Raloxifene reduces macrophage accumulation and matrix metalloproteinase expression in carotid lesions of ovariectomized cholesterol fed rabbits. Circulation (in press).

  62. Barrett-Conner E, Grady D, Sashegyi A, Anderson PW, Cox DM, Harper KD. Effects of raloxifene on serum lipids and clinical cardiovascular events in osteoporotic post-menopausal women: Multiple outcomes of raloxifene evaluation. J Amer College Cardiol 2001;38:608.

    Google Scholar 

  63. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Steward HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifene for breast cancer in a randomized trial. British Med J 1995;311:977-980.

    Google Scholar 

  64. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-? and-? mRNA in the rat central nervous system. J Comp Neurol 1997;388:507-525.

    Google Scholar 

  65. Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC, Plymate SR. Cognitive and neuroendocrine response to transdermal oestrogen in post-menopausal women with Alzaheimer's Disease; Results of a placebo-controlled, double blind, pilot study. Physchoneuroendocrinology 1999;24:657-677.

    Google Scholar 

  66. Merchenthaler I, Funkhouser JM, Carver JM, Lundeen SG, Ghosh K. Winneker RC. The effect of estrogenes and antiestrogens in a rat model for hot flush. Maturitas 1998;30:307-316.

    Google Scholar 

  67. Bryant HU, Bales KR, Paul SM, Yang H, Cole HW, Walker-Daniels J, McEwen BS, Chow H, Santerre RF. Estrogen agonist effects of selective estrogen receptor modulators in ovariectomized rat braom. Soc Neurosci Abstr 1977;23:2377.

    Google Scholar 

  68. Wu X, Glinn MA, Ostrowski NL, Su Y, Ni B, Cole HW, Bryant HU, Paul SM. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res 1999;847:98-104.

    Google Scholar 

  69. Nilsen J, Mor G, Naftolin F. Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause 1998;5:211-216.

    Google Scholar 

  70. Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH. Raloxifene hydrochloride, a selective estrogen receptor modulator: Safety assessment of effects on cognitive function and mood in post-menopausal women. Psychoneuroendocrinology 1999;24:115-128.

    Google Scholar 

  71. McDonnel DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of anti-estrogens. Mol Endocrinol 1995;9:659-669.

    Google Scholar 

  72. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors ? and ?. Endocrinology 1997;138:863-870.

    Google Scholar 

  73. Gize EA, Venugopalan M, Glasebrook AL, Yang NN. Characterization of raloxifene binding and transactivation properties of the estrogen receptor-beta. J Bone Mineral Res 1997;12(Suppl. 1):S428.

    Google Scholar 

  74. Khaholz BP, Renaud JP. Conformational adaptation of agonists to the human nuclear receptor RAR gamma. Nat Struct Biol 1998;5:199-202.

    Google Scholar 

  75. Mograno MM, Chang W, Katzenellenbogen BS. An estrogen receptor selective corepressor: Cloning and characterization. Endocrinology, 1998;98:96-104.

    Google Scholar 

  76. Yang NN, Venugopalan M, Hardilar S, Glasebrook AL. Identification of an estrogen response element activated by a metabolite of 17?-estradiol and raloxifene. Science 1996;273:1222-1225.

    Google Scholar 

  77. Bryant HU, Wilson PK, Adrian MD, Cole HW, Phillips DL, Dodge JA, Grese TA, Sluka JP, Glasebrook AL. Selective estrogen receptor modulators: Pharmacological profile in the rat uterus. J Soc Gynecol Invest 1996;3:152A.

    Google Scholar 

  78. Turner RT, Evans GL, Sluka JP, Adrian MD, Bryant HU, Turner CH, Sato M. Differential responses of estrogen target tissues including bone to clomiphene, enclomiphene and zuclomiphene. Endocrinology 1998;139:3712-3720.

    Google Scholar 

  79. Nuttall ME, Bradbeer JN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H, Rehm S, Gowen M. Idoxifene: A novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology 1998;139:5224-5234.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lilly Research Laboratories, Indianapolis, IN, USA

    Henry U. Bryant

Authors
  1. Henry U. Bryant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry U. Bryant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bryant, H.U. Selective Estrogen Receptor Modulators. Rev Endocr Metab Disord 3, 231–241 (2002). https://doi.org/10.1023/A:1020076426727

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020076426727

Search

Navigation